THE BENEFIT OF ADDITION OF CARBOPLATIN TO ADRIAMYCIN / CYCLOPHOSPHAMIDE / PACLITAXEL AS ADJUVANT CHEMOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER
Doaa Atef Mohammed Soliman;
Abstract
B
reast cancer is the most common cancer among women in the United States, the second most common cause of cancer death. In 2010, an estimated 207,090 new cases of breast cancer were diagnosed in the United States.
Triple-negative breast cancers are
reast cancer is the most common cancer among women in the United States, the second most common cause of cancer death. In 2010, an estimated 207,090 new cases of breast cancer were diagnosed in the United States.
Triple-negative breast cancers are
Other data
| Title | THE BENEFIT OF ADDITION OF CARBOPLATIN TO ADRIAMYCIN / CYCLOPHOSPHAMIDE / PACLITAXEL AS ADJUVANT CHEMOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER | Other Titles | اهميــة اضافـــة عـقــار الكــاربـوبــلاتـيـن الى عقارات الادريامايسين و السيكلوفوسفاميد والباكليتاكسيل فى سرطان الثدى الثلاثى السلبي | Authors | Doaa Atef Mohammed Soliman | Keywords | THE BENEFIT OF ADDITION OF CARBOPLATIN TO ADRIAMYCIN / CYCLOPHOSPHAMIDE / PACLITAXEL AS ADJUVANT CHEMOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER | Issue Date | 2011 | Description | B reast cancer is the most common cancer among women in the United States, the second most common cause of cancer death. In 2010, an estimated 207,090 new cases of breast cancer were diagnosed in the United States. Triple-negative breast cancers are |
Attached Files
| File | Size | Format | |
|---|---|---|---|
| 104139Doaa Atef Thesis Final (1-10-2011).pdf | 361.21 kB | Adobe PDF | View/Open |
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.